<DOC>
	<DOC>NCT01828619</DOC>
	<brief_summary>The purpose of this study is to determine whether the new RIC regimen, containing of low dose of Bu (9.6mg/kg)and fludarabine without ATG, is suitable and effective in treating aged and/or intolerable patients with hematologic malignant disease, who undergoes allogenic stem cell transplantation.</brief_summary>
	<brief_title>Study of New RIC Regimen of BuFlu in Older and/or Intolerable Patients</brief_title>
	<detailed_description />
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>diagnosed of hematologic malignant disease will undergo HLA matced HSCT age &gt;=55years &lt;55year and intolerable to standard myeloablative conditioning KPS status &lt;70 cardiac EF&lt;50% creatine clearance &lt;50 ml/min ALT more than 10 times of upper normal limit</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Hematopoietic Stem Cell Transplantation</keyword>
	<keyword>Busulfan</keyword>
	<keyword>Fludarabine</keyword>
</DOC>